期刊
LEUKEMIA & LYMPHOMA
卷 56, 期 7, 页码 2105-2113出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.981175
关键词
Prognosis; transformation; MSI2; leukemia; stem cell
资金
- Berliner Krebsgesellschaft e.V. [KAFF201401]
- Novartis
- Wilhelm-Sander Stiftung [2011.018.1]
- Deutsche Jose Carreras Leukamie-Stiftung Fund [DJCLS 10/23]
- Leukaemia Lymphoma NI
- Leukaemia & Lymphoma NI [R2536CNR] Funding Source: researchfish
A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p < 0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p < 0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABLI mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据